INNOVATIONS IN Regulatory Science AWARDS

DECEMBER 8, 2020
6–7:30 PM (EST)
WELCOME TO OUR 2020 INNOVATIONS IN REGULATORY SCIENCE AWARDS CELEBRATION.

This evening, we recognize more than excellence in regulatory science. We are celebrating the vision, invention, and patient impact exemplified by the achievements of our Leadership, Innovation, and Advocacy/Policy honorees.

2020 has been an interesting year and has presented us with many unexpected challenges — as well as opportunities to work and partner in new ways. The COVID-19 Evidence Accelerator is one example of how the regulatory field is coming together to answer key diagnostic and therapeutic questions as the world responds to the pandemic. We are proud to collaborate with so many of you on this effort and our other pandemic response projects.

Thank you for partnering with us in this memorable year, and thank you for joining us for the Innovations in Regulatory Science Awards. We know there are many demands on your time and energy. We hope our event inspires you and re-energizes you as we focus on helping Americans live longer, stronger, and healthier lives.
PROGRAM

Welcome
Ellen V. Sigal, PhD
Chair, Board of Directors, Reagan-Udall Foundation for the FDA

Lynne Zydowsky, PhD
Chief Science Officer, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments
Presenting Sponsor

Remarks
Stephen Hahn, MD
Commissioner of Food and Drugs, U.S. Food and Drug Administration

Susan C. Winckler, RPh, Esq.
Chief Executive Officer, Reagan-Udall Foundation for the FDA

Recognition of Special Guests
Richard Schilsky, MD
Vice Chair, Board of Directors, Reagan-Udall Foundation for the FDA

Award Presentations
LEADERSHIP AWARD
Amy Abernethy, MD, PhD
Principal Deputy Commissioner, U.S. Food and Drug Administration

INNOVATION AWARD
Friends of Cancer Research
Accepted by Jeff Allen, PhD, President & CEO

ADVOCACY/POLICY AWARD
The Michael J. Fox Foundation for Parkinson’s Research
Accepted by Michael J. Fox, Deborah W. Brooks, Todd Sherer, PhD —Leadership of The Michael J. Fox Foundation for Parkinson’s Research

Panel Discussion
“Advancing Innovation in a Pandemic: Former Commissioner Perspectives on the Enduring Impact of COVID-19”
Robert M. Califf, MD, MACC, 22nd Commissioner of Food and Drugs
Margaret A. Hamburg, MD, 21st Commissioner of Food and Drugs
Mark B. McClellan, MD, PhD, 18th Commissioner of Food and Drugs
Andrew C. von Eschenbach, MD, 20th Commissioner of Food and Drugs
From the day you’re born, we never stop taking care of you.

We never stop working to make your life healthier. That’s why we’re working to fight the COVID-19 pandemic and developing robotics to find and treat cancer. Why we’re restoring heart rhythms, relieving depression, controlling HIV and combating multidrug-resistant tuberculosis.

At Johnson & Johnson, we’re not just a baby company. We’re creating life-saving medicines, vaccines and medical technologies. And partnering with both public and private sectors to make sure everyone has access to care.

Keeping you healthy your whole life is our life’s work.

Johnson & Johnson

©2020

BOARD OF DIRECTORS

Ellen V. Sigal, PhD
BOARD CHAIR
Chair and Founder, Friends of Cancer Research

Richard L. Schilsky, MD
VICE CHAIR
Chief Medical Officer and Executive Vice President, American Society of Clinical Oncology

Jonathan Leff, MBA
FINANCE CHAIR
Partner, Deerfield Management Chairman, Deerfield Institute

Kay Holcombe, MS
SECRETARY
Senior Advisor, Milken Institute Center for Public Health

Edward John Allera, JD
Shareholder and Co-Chair, Food and Drug Practice, Buchanan Ingersoll & Rooney PC

Georges C. Benjamin, MD
Executive Director, American Public Health Association

Allan Coukell, BScPharm
Senior Vice President, Public Policy, Civica Rx

Helen B. Darling, MA
Strategic Advisor on Health Benefits and Health Care

Molly Fogarty
Vice President, Government Relations & Public Affairs, Nestlé

Sally J. Greenberg, JD
Executive Director, National Consumers League

Adrian F. Hernandez, MD
Vice Dean for Clinical Research, Duke University School of Medicine

Garry Neil, MD
Chief Scientific Officer, Cerecor Inc.

Andrew C. von Eschenbach, MD
20th Commissioner of the FDA President, Samaritan Health Initiatives

Lynne Zydowsky, PhD
Co-founder/President, Alexandria Summit
Chief Science Officer, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments President, Zydowsky Consultants, LLC

SENIOR ADVISOR TO THE BOARD

Mark McClellan, MD, PhD
18th Commissioner of the FDA Director, Duke-Margolis Center for Health Policy Margolis Professor of Business, Medicine and Health Policy, Duke University

EX-OFFICIO

Stephen M. Hahn, MD
Commissioner of Food and Drugs, U.S. Food and Drug Administration

Francis S. Collins, MD, PhD
Director, National Institutes of Health

STAFF LEADERSHIP

Susan C. Winckler, RPh, Esq.
Chief Executive Officer

©2020
2020 has been an extraordinarily demanding year for all of us, but especially for the dedicated staff of the FDA, who have been challenged, nearly every day, with a new facet of the COVID-19 pandemic. Please know how much we all appreciate the work you do. Thank you for your dedication and tireless focus during this global crisis.

By putting lives first, we’ve created a legacy that lasts

For nearly 130 years, we have tackled some of the world’s biggest health challenges and provided hope in the fight against disease, for both people and animals. Today, we continue our commitment to be the premier research-intensive biopharmaceutical company in pursuit of medical breakthroughs that benefit patients and society for today, tomorrow and generations to come.
Amy P. Abernethy MD, PhD
Principal Deputy Commissioner
Office of the Commissioner
U.S. Food and Drug Administration

Dr. Amy Abernethy oversees FDA’s daily operations and high-priority, cross-Center initiatives. While her charge is complex, she follows a simple rule: always innovate with the patient in the forefront.

A leader and pioneer in the use of real-world evidence (RWE), Dr. Abernethy’s conviction that patient care should be informed by reliable data is evident throughout her career — and especially during her time at FDA. She works every day to leverage health data to inform regulatory decisions, advance medical innovation, and improve care for patients.

Dr. Abernethy’s leadership, commitment, and passion have been especially critical during the COVID-19 global pandemic. She has built important partnerships to speed the use of RWE in our nation’s understanding and response to the disease, imploring researchers to “learn what we can as soon as we can.” She is instrumental in multiple collaborations, including the COVID-19 Evidence Accelerator, to ensure data integrity while moving quickly to establish the natural history of COVID-19, better understand and apply therapeutic learnings, and expand real-world data efforts into the diagnostics and testing arena.

Prior to joining FDA, Dr. Abernethy, a hematologist/oncologist and palliative medicine physician, served as Chief Medical Officer, Chief Scientific Officer, and Senior Vice President for Oncology at Flatiron Health and in multiple positions at Duke University School of Medicine.
Friends of Cancer Research (Friends) is working to accelerate policy change, support groundbreaking science, and deliver new therapies to patients quickly and safely.

A leader in the use of real-world evidence (RWE), Friends is working to help researchers better grasp the full potential of real-world data. Their Real-World Evidence Pilot Projects 1.0 and 2.0 engage multiple data partners, international populations, and oncology disease settings to create thorough recommendations on the role of real-world data on clinical research, drug development, and regulatory processes.

The projects culminated in the publication of “Recommendations for Use of Real-World Evidence in Oncology: Lessons Learned from the Friends of Cancer Research Real-World Evidence Framework,” outlining a replicable process for assembling fit-for-purpose datasets and a common real-world protocol and provides recommendations for developing an RWE framework.

In response to the COVID-19 crisis, Friends collaborated with the Reagan-Udall Foundation for the FDA to create the COVID-19 Evidence Accelerator, a unique venue for data organizations, government and academic researchers, and health systems to design quick-turn-around queries and share their results. Real-world data can be a critical tool to help swiftly address the many unknowns of COVID-19, especially for individuals with cancer and other underlying conditions who may be particularly vulnerable during the pandemic.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is changing the landscape of Parkinson’s research. Working to find a cure and ensure better therapies, MJFF spearheads an aggressively funded research agenda and advances understanding and treatment of the disease.

MJFF leverages expert perspective and global contacts to create an open, collaborative, and replicable research environment that leads to faster results for the six million people living with Parkinson’s worldwide. MJFF-funded investigations have resulted in two recent FDA approvals of new Parkinson’s therapies and countless more therapeutic programs that have attracted follow-on funding and made it one step closer to the hands of Parkinson’s patients and families.

The flagship Parkinson’s Progression Markers Initiative has built the most robust dataset and biosample library in the history of Parkinson’s research. It is the cornerstone of MJFF’s growing understanding of Parkinson’s pathology and clinical experience and has heavily influenced emerging clinical trials. In fact, data from the initiative has been downloaded more than 6.5 million times.

MJFF puts patients first and is on a mission to connect with every person with Parkinson’s. A powerful patient force on Capitol Hill, MJFF regularly educates members of Congress on issues important to the Parkinson’s community and pushes for policies that spur faster knowledge. MJFF defines success simply: scientific solutions that produce tangible improvements in patients’ lives.
The Reagan-Udall Foundation for the FDA thanks our Awards Committee for their commitment to the Innovations in Regulatory Science Awards.

Michael Boyle, MD  
President and CEO, Cystic Fibrosis Foundation

Arthur L. Caplan, PhD  
Drs. William F. and Virginia Connolly Mitty Professor of Bioethics, Department of Population Health; Director, Division of Medical Ethics, NYU Langone

Theresa M. Mullin, PhD  
Associate Director for Strategic Initiatives, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Garry Neil, MD  
Board Member, Reagan-Udall Foundation for the FDA

Andrew C. von Eschenbach, MD  
Board Member, Reagan-Udall Foundation for the FDA

Joanne Waldstreicher, MD  
Chief Medical Officer, Johnson & Johnson

Lynne Zydowsky, PhD  
Board Member, Reagan-Udall Foundation for the FDA

Creating Possible

For more than 30 years, Gilead has created breakthroughs once thought impossible for people living with life-threatening diseases. We are a leading biopharmaceutical company with a pioneering portfolio and ever-expanding pipeline of investigational medicines.

Our commitment goes well beyond science. We innovate with the goal of eliminating barriers and providing access to healthcare for people who need it most.

For more information, please visit www.gilead.com.

Gilead is proud to support the Reagan Udall Annual Innovations in Regulatory Science Awards.

© 2020 Gilead Sciences, Inc.

Greenleaf Health

A leading FDA regulatory consulting firm guiding companies through the changing FDA landscape.

OUR EXPERIENCE. YOUR SUCCESS.

www.greenleafhealth.com
Earlier this year, at FDA’s request, the Reagan-Udall Foundation for the FDA established the COVID-19 Evidence Accelerator in collaboration with Friends of Cancer Research. We express our thanks and gratitude to all of the academic, industry, and government groups that have participated in this effort.

We extend special appreciation to the following organizations that have been active participants in one or more of the Parallel Analysis workgroups tackling critical questions of regulatory importance in the worldwide fight against COVID-19. These include institutions which have provided data and/or key advice in the analysis of real-world data regarding COVID-19 treatment and testing.

- Aetion, Inc.
- Ciox Health
- COTA Healthcare
- Dascena
- Datavant, Inc.
- Eli Lilly and Company
- Epic Systems
- Gilead Sciences, Inc.
- Hackensack Meridian Health
- Harvard University
- Health Catalyst
- HealthVerity
- Margolis Center for Health Policy – Duke University
- Mayo Clinic
- The MITRE Corporation
- Northwestern University
- PCORnet
- Regenstrief Institute
- Sentinel Initiative (Harvard Pilgrim Health Care Institute, University of Pennsylvania, FDA)
- Sutter Health
- Syapse, Inc.
- Target RWE
- TriNetX, Inc.
- UnitedHealth Group
- United States Department of Veterans Affairs
- University of California Health Systems
- Yale University

To learn more, please visit EvidenceAccelerator.org.
We celebrate
the work and
contributions of this year’s
Innovations in Regulatory
Science Award Recipients.

Thank you for protecting
our nation’s public health
through your dedicated research,
leadership, and advocacy in
science—the essential
foundation for quality
and innovation.

Dedicated to helping patients in the rare
disease community with unmet medical needs

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company committed
to creating new therapeutics to combat serious, debilitating diseases.
ultragenyx.com

As biopharmaceutical researchers keep searching for breakthrough cures
they don’t have to look far for inspiration.
In this era of medicine, where breakthroughs are transforming prevention and treatment options,
PhRMA is committed to fixing America’s health care system the right way.

Congratulations
to our 2020
Innovations in
Regulatory Science
Awardees!
The Reagan-Udall Foundation for the Food and Drug Administration is an independent 501(c)(3) organization created by Congress “to advance the mission of the FDA to modernize medical, veterinary, food, food ingredient, and cosmetic product development, accelerate innovation, and enhance product safety.”

The Foundation embodies FDA’s vision of collaborative innovation to address regulatory science challenges of the 21st century and assist in the creation of new applied scientific knowledge, tools, standards, and approaches the FDA needs to evaluate products more effectively, predictably, and efficiently, and thereby enhance the FDA’s ability to protect and promote the health of the American public. The Foundation serves as a crucial conduit between FDA and the public, providing a means for FDA to interact directly with stakeholders, including industry and consumers. The Foundation does not participate in regulatory decision-making or offer advice to FDA on policy matters.

Mission
Advance the mission of the Food and Drug Administration to modernize product development, accelerate innovation, and enhance product safety

Vision
A world where regulation informed by science improves product innovation and public health

Core Values
• Engagement
• Innovation
• Evidence

Mission Pillars
• Research & Analysis
• Patient, Provider & Consumer Services
• Education
• Engagement